MacroGenics (MGNX) Competitors

MacroGenics logo
$1.96 -0.02 (-1.01%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$1.96 +0.01 (+0.26%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

MGNX vs. IMMX, CAPR, CBIO, RGNX, and NGNE

Should you buy MacroGenics stock or one of its competitors? MacroGenics's main competitors and comparable companies include Immix Biopharma (IMMX), Capricor Therapeutics (CAPR), Crescent Biopharma (CBIO), REGENXBIO (RGNX), and Neurogene (NGNE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MacroGenics compare to Immix Biopharma?

Immix Biopharma (NASDAQ:IMMX) and MacroGenics (NASDAQ:MGNX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

In the previous week, Immix Biopharma had 19 more articles in the media than MacroGenics. MarketBeat recorded 23 mentions for Immix Biopharma and 4 mentions for MacroGenics. Immix Biopharma's average media sentiment score of 0.37 beat MacroGenics' score of -0.28 indicating that Immix Biopharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immix Biopharma
5 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
MacroGenics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Immix Biopharma has a net margin of 0.00% compared to MacroGenics' net margin of -45.37%. Immix Biopharma's return on equity of -24.93% beat MacroGenics' return on equity.

Company Net Margins Return on Equity Return on Assets
Immix BiopharmaN/A -24.93% -23.55%
MacroGenics -45.37%-246.62%-31.36%

Immix Biopharma currently has a consensus price target of $24.14, indicating a potential upside of 246.88%. MacroGenics has a consensus price target of $8.50, indicating a potential upside of 333.67%. Given MacroGenics' higher probable upside, analysts plainly believe MacroGenics is more favorable than Immix Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immix Biopharma
1 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.78
MacroGenics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by company insiders. Comparatively, 13.6% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Immix Biopharma has higher earnings, but lower revenue than MacroGenics. Immix Biopharma is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Immix BiopharmaN/AN/A-$29.44M-$0.83N/A
MacroGenics$149.50M0.84-$74.62M-$0.81N/A

Immix Biopharma has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.33, meaning that its stock price is 33% more volatile than the broader market.

Summary

Immix Biopharma beats MacroGenics on 9 of the 15 factors compared between the two stocks.

How does MacroGenics compare to Capricor Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and MacroGenics (NASDAQ:MGNX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, dividends, media sentiment, valuation, analyst recommendations and profitability.

MacroGenics has higher revenue and earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Capricor Therapeutics$22.27M19.76-$105.04M-$2.64N/A
MacroGenics$149.50M0.84-$74.62M-$0.81N/A

Capricor Therapeutics currently has a consensus target price of $30.09, indicating a potential upside of 297.61%. MacroGenics has a consensus target price of $8.50, indicating a potential upside of 333.67%. Given MacroGenics' stronger consensus rating and higher possible upside, analysts clearly believe MacroGenics is more favorable than Capricor Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capricor Therapeutics
1 Sell rating(s)
5 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.36
MacroGenics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

In the previous week, Capricor Therapeutics had 14 more articles in the media than MacroGenics. MarketBeat recorded 18 mentions for Capricor Therapeutics and 4 mentions for MacroGenics. Capricor Therapeutics' average media sentiment score of 0.16 beat MacroGenics' score of -0.28 indicating that Capricor Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Capricor Therapeutics
3 Very Positive mention(s)
3 Positive mention(s)
9 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
MacroGenics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Capricor Therapeutics has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market. Comparatively, MacroGenics has a beta of 1.33, suggesting that its stock price is 33% more volatile than the broader market.

Capricor Therapeutics has a net margin of 0.00% compared to MacroGenics' net margin of -45.37%. Capricor Therapeutics' return on equity of -56.71% beat MacroGenics' return on equity.

Company Net Margins Return on Equity Return on Assets
Capricor TherapeuticsN/A -56.71% -42.71%
MacroGenics -45.37%-246.62%-31.36%

21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by insiders. Comparatively, 13.6% of MacroGenics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

MacroGenics beats Capricor Therapeutics on 10 of the 16 factors compared between the two stocks.

How does MacroGenics compare to Crescent Biopharma?

MacroGenics (NASDAQ:MGNX) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

MacroGenics has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

Crescent Biopharma has a net margin of 0.00% compared to MacroGenics' net margin of -45.37%. Crescent Biopharma's return on equity of -88.20% beat MacroGenics' return on equity.

Company Net Margins Return on Equity Return on Assets
MacroGenics-45.37% -246.62% -31.36%
Crescent Biopharma N/A -88.20%-77.36%

MacroGenics presently has a consensus target price of $8.50, suggesting a potential upside of 333.67%. Crescent Biopharma has a consensus target price of $33.17, suggesting a potential upside of 155.13%. Given MacroGenics' higher possible upside, research analysts plainly believe MacroGenics is more favorable than Crescent Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MacroGenics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Crescent Biopharma
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86

MacroGenics has higher revenue and earnings than Crescent Biopharma. MacroGenics is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MacroGenics$149.50M0.84-$74.62M-$0.81N/A
Crescent Biopharma$15M33.71-$153.94M-$6.35N/A

96.9% of MacroGenics shares are held by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are held by institutional investors. 13.6% of MacroGenics shares are held by insiders. Comparatively, 24.8% of Crescent Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Crescent Biopharma had 1 more articles in the media than MacroGenics. MarketBeat recorded 5 mentions for Crescent Biopharma and 4 mentions for MacroGenics. Crescent Biopharma's average media sentiment score of 0.08 beat MacroGenics' score of -0.28 indicating that Crescent Biopharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MacroGenics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Crescent Biopharma
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Crescent Biopharma beats MacroGenics on 11 of the 17 factors compared between the two stocks.

How does MacroGenics compare to REGENXBIO?

REGENXBIO (NASDAQ:RGNX) and MacroGenics (NASDAQ:MGNX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

REGENXBIO currently has a consensus target price of $23.18, suggesting a potential upside of 223.77%. MacroGenics has a consensus target price of $8.50, suggesting a potential upside of 333.67%. Given MacroGenics' higher probable upside, analysts plainly believe MacroGenics is more favorable than REGENXBIO.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
REGENXBIO
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.69
MacroGenics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

MacroGenics has a net margin of -45.37% compared to REGENXBIO's net margin of -113.85%. REGENXBIO's return on equity of -203.98% beat MacroGenics' return on equity.

Company Net Margins Return on Equity Return on Assets
REGENXBIO-113.85% -203.98% -42.54%
MacroGenics -45.37%-246.62%-31.36%

MacroGenics has lower revenue, but higher earnings than REGENXBIO. MacroGenics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
REGENXBIO$170.44M2.78-$193.88M-$3.21N/A
MacroGenics$149.50M0.84-$74.62M-$0.81N/A

88.1% of REGENXBIO shares are held by institutional investors. Comparatively, 96.9% of MacroGenics shares are held by institutional investors. 14.2% of REGENXBIO shares are held by company insiders. Comparatively, 13.6% of MacroGenics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

REGENXBIO has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, MacroGenics has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

In the previous week, MacroGenics had 3 more articles in the media than REGENXBIO. MarketBeat recorded 4 mentions for MacroGenics and 1 mentions for REGENXBIO. REGENXBIO's average media sentiment score of 0.00 beat MacroGenics' score of -0.28 indicating that REGENXBIO is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
REGENXBIO
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
MacroGenics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

REGENXBIO beats MacroGenics on 9 of the 17 factors compared between the two stocks.

How does MacroGenics compare to Neurogene?

MacroGenics (NASDAQ:MGNX) and Neurogene (NASDAQ:NGNE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

MacroGenics presently has a consensus target price of $8.50, suggesting a potential upside of 333.67%. Neurogene has a consensus target price of $79.57, suggesting a potential upside of 259.24%. Given MacroGenics' higher probable upside, equities research analysts clearly believe MacroGenics is more favorable than Neurogene.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MacroGenics
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40
Neurogene
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
2 Strong Buy rating(s)
3.00

In the previous week, MacroGenics had 2 more articles in the media than Neurogene. MarketBeat recorded 4 mentions for MacroGenics and 2 mentions for Neurogene. Neurogene's average media sentiment score of 0.59 beat MacroGenics' score of -0.28 indicating that Neurogene is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MacroGenics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Neurogene
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

96.9% of MacroGenics shares are held by institutional investors. Comparatively, 52.4% of Neurogene shares are held by institutional investors. 13.6% of MacroGenics shares are held by company insiders. Comparatively, 11.7% of Neurogene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MacroGenics has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MacroGenics$149.50M0.84-$74.62M-$0.81N/A
Neurogene$930K493.02-$90.35M-$5.09N/A

Neurogene has a net margin of 0.00% compared to MacroGenics' net margin of -45.37%. Neurogene's return on equity of -44.36% beat MacroGenics' return on equity.

Company Net Margins Return on Equity Return on Assets
MacroGenics-45.37% -246.62% -31.36%
Neurogene N/A -44.36%-40.61%

MacroGenics has a beta of 1.33, suggesting that its share price is 33% more volatile than the broader market. Comparatively, Neurogene has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market.

Summary

MacroGenics beats Neurogene on 9 of the 17 factors compared between the two stocks.

Get MacroGenics News Delivered to You Automatically

Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MGNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MGNX vs. The Competition

MetricMacroGenicsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$125.26M$3.92B$7.44B$10.86B
Dividend YieldN/A3.79%2.51%4.69%
P/E Ratio-2.4223.0732.5628.72
Price / Sales0.8415.358.005.34
Price / CashN/A21.9220.2520.77
Price / Book5.034.124.343.51
Net Income-$74.62M-$24.08M$3.51B$394.12M
7 Day Performance-10.91%-9.85%-8.07%-8.97%
1 Month Performance-46.01%-12.77%-10.29%-11.61%
1 Year Performance40.00%-7.99%-4.70%-11.21%

MacroGenics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MGNX
MacroGenics
2.0471 of 5 stars
$1.96
-1.0%
$8.50
+333.7%
+40.0%$125.26M$149.50MN/A293
IMMX
Immix Biopharma
2.9982 of 5 stars
$7.20
-3.7%
$24.14
+235.3%
+60.7%$515.09MN/AN/A21
CAPR
Capricor Therapeutics
3.0087 of 5 stars
$8.41
+1.3%
$30.09
+257.8%
+31.6%$488.97MN/AN/A231
CBIO
Crescent Biopharma
2.7939 of 5 stars
$13.04
-3.4%
$33.17
+154.3%
-0.5%$484.31M$10.84MN/A44
RGNX
REGENXBIO
2.3391 of 5 stars
$7.24
-1.1%
$23.18
+220.2%
-39.3%$478.73M$153.91MN/A371

Related Companies and Tools


This page (NASDAQ:MGNX) was last updated on 11/22/2026 by MarketBeat.com Staff.
From Our Partners